Literature DB >> 1607706

IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations.

R J Hamill1, D M Musher, J E Groover, P J Zavell, D A Watson.   

Abstract

Intravenous immunoglobulin replacement is recommended for immunoglobulin deficiency, but comparison of the efficacy of intravenous immunoglobulin preparations (IVIGs) has been hindered by the lack of standardized assays to measure immunoglobulin levels against important bacterial pathogens. IgG reactive with five commonly isolated serotypes of Streptococcus pneumoniae in four commercially available IVIGs was measured by ELISA. Specific antibody to capsular polysaccharide was quantitated before and after adsorption with cell wall polysaccharide (CWPS). All IVIGs contained measurable levels of antibody to the five pneumococcal serotypes, although the levels against an individual serotype varied by as much as sevenfold from one preparation to another. Each IVIG also contained substantial concentrations of IgG reactive with CWPS. The amount of each IVIG that protected mice was nearly identical after the doses were adjusted on the basis of specific IgG measured by ELISA, thereby providing proof in vivo of the validity of this in vitro assay system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607706     DOI: 10.1093/infdis/166.1.38

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Antibiotics modulate vaccine-induced humoral immune response.

Authors:  P C Woo; H W Tsoi; L P Wong; H C Leung; K Y Yuen
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Recurrent systemic pneumococcal infection in an immunocompromised patient.

Authors:  R R Reinert; A Büssing; H Kierdorf; O Kühnemund; A Kaufhold
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

3.  Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Authors:  Malgorzata G Mikolajczyk; Nelydia F Concepcion; Theresa Wang; Douglas Frazier; Basil Golding; Carl E Frasch; Dorothy E Scott
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production.

Authors:  T Darville; L B Milligan; K K Laffoon
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

Authors:  L De Hennezel; F Ramisse; P Binder; G Marchal; J M Alonso
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 6.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

7.  Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.

Authors:  W T Jansen; J Gootjes; M Zelle; D V Madore; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

Review 8.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

Review 9.  Respiratory infections: community-acquired pneumonia and newer microbes.

Authors:  H Y Reynolds
Journal:  Lung       Date:  1996       Impact factor: 2.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.